drugset / Trial / NCT05411965

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

NCT05411965

Phase 1 Completed 48 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.

Timeline

Start
2022-04-28
Primary completion
2022-07-03
Completion
2022-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral